Sample Issues
Freely view the following issues of The Medical Letter and Treatment Guidelines.
To read these articles you will need a free Adobe® Reader.
The Medical Letter
January 24, 2011 (Issue 1356)
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Botulinum Toxin for Chronic Migraine
In Brief: Denosumab for Bone Metastases
To read these articles you will need a free Adobe® Reader.
The Medical Letter
January 24, 2011 (Issue 1356)
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Botulinum Toxin for Chronic Migraine
In Brief: Denosumab for Bone Metastases
Canadian-Adapted Version: January 24, 2011 (Issue 1356)
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Botulinum Toxin for Chronic Migraine
In Brief: Denosumab for Bone Metastases
French: 21 février 2011 (M.L. 1356)
Céftaroline fosamil (Teflaro) - une nouvelle céphalosporine IV
Toxine botulinique pour traiter la migraine chronique
En Bref: Dénosumab pour traiter les métastases osseuses
March, 2011 (Issue 103)
Drugs for Lipids
Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoproteins return to pretreatment levels in 2-3 weeks.
Subscribe to The Medical Letter or Treatment Guidelines - Immediate online access!
